Abstract

Objective To evaluate laparoscopy assisted radio frequency ablation (LRFA) and percutaneous radiofrequency ablation ( PRFA ) for the treatment of hepatocellular carcinoma ( HCC ).Methods A total of 525 HCC patients were enrolled,including LRFA group of 78 cases with 106 tumor nodules,and PRFA group of 447 cases with 565 tumor nodules.Results ( 1 ) In LRFA group complete ablation rate was 97.17％ (103/106); in LRFA group complete ablation rate was 93.09％ (526/565)(x2 =2.523,P =0.112).(2)The 1,3,5 year overall survival rate was 96.15％,55.12％ and 38.46％in LRFA group and 93.73％,48.54％ and 31.54％ in PRFA group respectively ( x2 =0.699,1.151,1.447 ; P =0.403,0.283,0.229 ).The 1,3,5 year disease-free survival rate was 94.87％,43.58％ and 28.21％ in LRFA group and 93.73％,48.54％ and 31.54％ in PRFA group respectively (x2 =0.915,0.303,0.174; P=0.339,0.582,0.676).The average disease-free survival time was 22.25 months in LRFA group and 21.53 months in PRFA group respectively.(3)The serious complications was 0％ (0/78)in LRFA group and 1.34％ ( 6/447 ) in PRFA group respectively.( 4 ) Recurrence rate was 23.07％(18/78) in LRFA group,and 34.89％ (156/447) in PRFA group ( x2 =4.189,P =0.041 ).Conclusions The therapeutical effect of LRFA equals that of PRFA,while enjoying lower recurrence rate,no serious complications and higher treatment safety. Key words: Carcinoma, hepatocellular; Laperoscopy; Radio frequency ablation

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.